Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.
复制标题
DOI：
10.1007/978-3-642-74621-5_14
复制
发表时间：
1988
期刊：
影响因子：
20.3
通讯作者：
Meng-er Huang;Yu-chen Ye;Shu-rong Chen;Jingren Chai;Jia-xiang Lu;Zhao Lin;Long-jun Gu;Zhen-yi Wang
中科院分区：
文献类型：
--
作者：
Meng-er Huang;Yu-chen Ye;Shu-rong Chen;Jingren Chai;Jia-xiang Lu;Zhao Lin;Long-jun Gu;Zhen-yi Wang
急性早幼粒细胞白血病(APL)被认为是急性髓系白血病(AML)中一个独特的实体。出血性素质常发生，并可导致迅速死亡。出血通常归因于血小板减少和/或弥漫性血管内凝血(DIC)，这被认为是由早幼粒细胞颗粒释放促凝血因子[1]所致。
Acute promyelocytic leukemia (APL) is considered to be a distinct entity among the acute myeloid leukemias (AMLs). Hemorrhagic diathesis often occurs and results in a rapid fatal outcome. The bleeding episodes are usually attributed to thrombocytopenia and/or disseminated intravascular coagulation (DIC), which is thought to result from the release of a procoagulant factor from the promyelocyte granules [1].